Puas yog dihydromyricetin zoo rau lub siab?
Dihydromyricetin Bulk Powderyog ib qho flavonoid compound feem ntau pom nyob rau hauv nplooj ntawm Ampelopsis pilosula (vine tshuaj yej), thiab tau txais kev saib xyuas thoob plaws hauv xyoo tas los no vim nws cov teebmeem hepatoprotective tseem ceeb. Cov hauv qab no yog ib qho kev taw qhia los ntawm peb yam: nws cov txheej txheem ntawm kev ua, nws tiv thaiv cov kab mob sib txawv ntawm daim siab, thiab nws txoj kev nyab xeeb.
Ib. Core Protection Mechanism
| Mechanism | Hom Kev Ua Haujlwm | Txoj kev tseem ceeb / Lub Hom Phiaj |
|---|---|---|
| Antioxidant | Scavenes reactive oxygen hom (ROS), txo oxidative kev nyuaj siab | AMPK/Sirt-1/PGC-1 txoj kev |
| Anti- mob | Inhibits tso tawm inflammatory cytokines | FXR/NLRP3, TLR4/MyD88/NF-κB |
| Kev tswj hwm lipid metabolism | Txo cov rog synthesis, txhawb kev rog rog | Txo TG, TC, LDL -C |
| Kho kev txhawb nqa | Induces hepatocyte proliferation | Txhawb nqa daim siab cov ntaub so ntswg regeneration |
Cov ntawv luv:
TG=Triglycerides
TC=Cov roj (cholesterol) tag nrho
LDL -C=Tsawg-Density Lipoprotein Cholesterol
2. Cov ntaub ntawv tshawb fawb tseem ceeb (Ntxiv raws li xav tau)
1. Cawv Kab Mob Siab
Hauv cov kev tshawb fawb nas ntawm cov kab mob cawv ntev ntev, kev kho mob dihydromyricetin txo qis transaminase los ntawm kwv yees li 45-60%, txo lub siab triglyceride los ntawm 50-70%, thiab txo qis hepatocellular steatosis thiab inflammatory cell infiltration.
2. Metabolic Fatty Liver Disease
Tam sim no qhov no yog thaj chaw uas muaj pov thawj siab tshaj plaws. Ib qho randomized, ob npaug - dig muag, placebo- tswj kev sim luam tawm xyoo 2025-2026 (55 tus neeg mob nrog MASLD, 12-hli kev cuam tshuam) pom:
- Qhov sib xyaw ua ke ntawm daim siab enzymes (ALT / GGT) yog 35% hauv pawg DHM ntxiv, piv rau tsuas yog 5% hauv pawg placebo (P=0.028).
- Glucose, tag nrho cov roj cholesterol, thiab LDL cov roj cholesterol tag nrho txo qis.
- Lub siab tawv qhov tseem ceeb tau qis dua qhov pib ntawm ob qho tib si 6 thiab 12 lub hlis.
Cov kws tshawb fawb tau xaus lus tias DHM ntxiv rau 6-12 lub hlis tuaj yeem txhim kho daim siab enzymes, lub siab tawv, thiab cov piam thaj thiab lipid metabolism hauv cov neeg mob MASLD.
3. Tshuaj-ua rau lub siab raug mob
Ib txoj kev tshawb fawb nas xyoo 2025 tau pom tias kev kho mob ua ntej nrog dihydromyricetin tuaj yeem txo qis hepatotoxicity tshwm sim los ntawm cov tshuaj tua kab mob cyclophosphamide, tshwm sim los ntawm kev txo qis transaminase, nce kev ua haujlwm antioxidant enzyme, thiab txo qis kev hloov pauv hauv siab. Nws cov txheej txheem tiv thaiv muaj feem xyuam rau kev txo qis oxidative kev nyuaj siab thiab tswj lub zog metabolism.
4. Preclinical Meta- tsom xam
Kev tshuaj xyuas cov txheej txheem luam tawm hauv * Frontiers hauv Kev Noj Qab Haus Huv * hauv lub Plaub Hlis 2026 (suav nrog 14 nas nas NAFLD qauv kev tshawb fawb) kom paub tseeb tias dihydromyricetin txo qis siab triglyceride, tag nrho cov roj cholesterol, transaminase, thiab inflammatory cytokine theem, thaum nce antioxidant enzyme thiab pAMPK / AMPK ratio. Cov kws tshawb fawb tau hu rau kev tsim qauv preclinical ntau dua thiab siab - kev tshawb fawb tib neeg zoo.
3. Kev soj ntsuam kev nyab xeeb (Nyem nthuav dav)
1. Kev ntsuam xyuas cov ntaub ntawv pov thawj
Raws li US LiverTox database, dihydromyricetin npajtsis tau pom tias muaj feem cuam tshuam nrog cov ntshav enzyme nce siab lossis kho mob rau daim siab mob. Qhov no yog qhov tsim nyog vim tias ntau cov tshuaj ntsuab tshuaj ntsuab muaj qhov sib txawv ntawm kev pheej hmoo hepatotoxicity.
2. Human Trial Data
Hauv 2025-2026 MASLD tib neeg sim:
- Qhov tshwm sim ntawm cov xwm txheej tsis zoo yog qhov zoo sib xws ntawm pawg DHM thiab pawg placebo (mob plab tsis xis nyob 5.0% vs. 3.3%; mob taub hau 3.3% vs. 5.0%)
- Tsis muaj qhov tshwm sim tsis zoo tshwm sim
- Txhua qhov xwm txheej tsis zoo yog me me mus rau nruab nrab thiab tsis ua rau kev kawm txog kev txiav tshuaj yeeb
3. Keeb kwm siv ib txwm siv
Dihydromyricetin yog lub luag haujlwm tseem ceeb ntawm cov tshuaj yej vine (Ampelopsis grossedentata yog qhov zoo tshaj plaws), uas tau siv los ua dej haus txhua hnub hauv qee thaj tsam ntawm Tuam Tshoj rau ntau pua xyoo, ib txwm siv rau kev kho mob hangover thiab tiv thaiv daim siab. Qhov no muab kev txhawb nqa ntxiv rau nws qhov profile kev nyab xeeb.
4. Kev xav txog kev pheej hmoo
| Pawg Risk | Kev piav qhia |
|---|---|
| Txoj Cai Tswjfwm | Muag raws li kev noj haus ntxiv, tsis yog FDA- pom zoo tshuaj; cov khoom zoo sib txawv |
| Cov pejxeem tshwj xeeb | Cov ntaub ntawv kev nyab xeeb tsis muaj rau cov poj niam cev xeeb tub / pub niam mis thiab cov neeg mob uas muaj kab mob siab heev |
| Cov tshuaj sib cuam tshuam | Kev sib cuam tshuam nrog CYP3A4-metabolized tshuaj tsis tau kawm ua haujlwm |
| Bioavailability | Tsawg qhov ncauj bioavailability (~ 4%) cuam tshuam rau kev kwv yees ntawm kev ua tau zoo |
| Ntev -Lub sij hawm nyab xeeb | Kev tshawb fawb tib neeg ntev tshaj plaws rau hnub tim yog 12 lub hlis; cov ntaub ntawv dhau tnws lub sij hawm tsis txaus |
4.Cov ntsiab lus ntawm Kev Tshawb Fawb Txog Tam Sim No (Nyob Nruab Nrab nthuav dav)
1. Pov thawj Pyramid
|
Pov Thawj Qib |
Hom kawm |
Quantity / Status |
Xaus |
|---|---|---|---|
|
Siab tshaj |
Human RCT |
1 kev kawm (n=55) |
Txhim kho daim siab enzymes thiab metabolic tsis nyob hauv MASLD |
|
Siab |
Preclinical Meta- tsom xam |
1 txoj kev tshawb fawb (14 kev tshawb fawb suav nrog) |
Quantitatively lees paub ntau-domain ua tau zoo |
|
Nruab nrab |
Phase I Human Trial |
1 tsis tu ncua |
Kev nyab xeeb thiab PK cov ntaub ntawv tseem tos (kawg 2025) |
|
Foundational |
Tsiaj Studies |
Kaum ob |
Tsis tu ncua qhia cov teebmeem tiv thaiv |
2.Main Strengths thiab txwv
Lub zog:
- Cov ntaub ntawv pov thawj preclinical tau zoo ib yam thiab siv tau los ntawm meta- tsom xam
- Lub siab - tib neeg RCT zoo tau pom cov txiaj ntsig zoo thawj zaug (35% vs. 5%)
- Kev ruaj ntseg profile zoo; Tsis muaj cov ntaub ntawv qhia txog kev mob hepatotoxicity hauv LiverTox
- Hauv -Kev tshawb fawb tob tob (AMPK, NLRP3, TLR4 txoj hauv kev, thiab lwm yam)
Kev txwv:
- Cov qauv me me hauv tib neeg kev tshawb fawb (tsuas yog 55 tus neeg mob); ywj siab validation xav tau
- Dosage tsis standardized; Tsawg bioavailability (~ 4%) yog ib qho teeb meem loj
- Tsis muaj cov ntaub ntawv tib neeg rau kev haus dej cawv rau daim siab, daim siab fibrosis, thiab lwm yam mob
- Lack of long-term safety data (>2 xyoos)
Dihydromyricetin Bulk Powdertiv thaiv daim siab los ntawm ntau lub tswv yim, suav nrog tshuaj tua kab mob antioxidant, tiv thaiv - mob, thiab kev tswj hwm lipid metabolism. Cov ntsiab lus tseem ceeb suav nrog RCT cov txiaj ntsig zoo hauv MASLD daim teb (lub siab enzyme normalization tus nqi 35% vs 5%) thiab qhov txuas ntxiv mus rau Phase I hauv kab mob siab. Zuag qhia tag nrho, cov pov thawj yog qhov zoo, tab sis tib neeg cov ntaub ntawv tsawg thiab tsis muaj bioavailability tseem muaj teeb meem los daws. Rau cov neeg siv txaus siab, nws raug nquahu kom siv qhov no los ua kev kho mob ntxiv raws li kev qhia ntawm tus kws kho mob thiab nws yuav tsum tsis txhob hloov txoj kev noj qab haus huv lossis kev kho tus qauv.
